• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤溶酶原激活物抑制剂-1在人肝脏以及健康或动脉粥样硬化血管壁中的表达。

Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls.

作者信息

Chomiki N, Henry M, Alessi M C, Anfosso F, Juhan-Vague I

机构信息

Laboratory of Hematology, CHU Timone, Marseille, France.

出版信息

Thromb Haemost. 1994 Jul;72(1):44-53.

PMID:7974374
Abstract

Individuals with elevated levels of plasminogen activator inhibitor type 1 are at risk of developing atherosclerosis. The mechanisms leading to increased plasma PAI-1 concentrations are not well understood. The link observed between increased PAI-1 levels and insulin resistance has lead workers to investigate the effects of insulin or triglyceride rich lipoproteins on PAI-1 production by cultured hepatocytes or endothelial cells. However, little is known about the contribution of these cells to PAI-1 production in vivo. We have studied the expression of PAI-1 in human liver sections as well as in vessel walls from different territories, by immunocytochemistry and in situ hybridization. We have observed that normal liver endothelial cells expressed PAI-1 while parenchymal cells did not. However, this fact does not refute the role of parenchymal liver cells in pathological states. In healthy vessels, PAI-1 mRNA and protein were detected primarily at the endothelium from the lumen as well as from the vasa vasorum. In normal arteries, smooth muscle cells were able to produce PAI-1 depending on the territory tested. In deeply altered vessels, PAI-1 expression was observed in neovessels scattering the lesions, in some intimal cells and in smooth muscle cells. Local increase PAI-1 mRNA described in atherosclerotic lesions could be due to the abundant neovascularization present in the lesion as well as a raised expression in smooth muscle cells. The increased PAI-1 in atherosclerosis could lead to fibrin deposit during plaque rupture contributing further to the development and progression of the lesion.

摘要

纤溶酶原激活物抑制剂1水平升高的个体有患动脉粥样硬化的风险。导致血浆PAI - 1浓度升高的机制尚不完全清楚。PAI - 1水平升高与胰岛素抵抗之间的关联促使研究人员研究胰岛素或富含甘油三酯的脂蛋白对培养的肝细胞或内皮细胞产生PAI - 1的影响。然而,对于这些细胞在体内PAI - 1产生中的作用知之甚少。我们通过免疫细胞化学和原位杂交研究了PAI - 1在人肝脏切片以及不同部位血管壁中的表达。我们观察到正常肝脏内皮细胞表达PAI - 1,而实质细胞不表达。然而,这一事实并不否定实质肝细胞在病理状态下的作用。在健康血管中,PAI - 1 mRNA和蛋白主要在内皮细胞的管腔以及血管滋养管中被检测到。在正常动脉中,平滑肌细胞能够根据所检测的部位产生PAI - 1。在严重病变的血管中,在散布于病变处的新生血管、一些内膜细胞和平滑肌细胞中观察到PAI - 1表达。动脉粥样硬化病变中描述的局部PAI - 1 mRNA增加可能是由于病变中存在丰富的新生血管以及平滑肌细胞中表达升高所致。动脉粥样硬化中PAI - 1增加可能导致斑块破裂时纤维蛋白沉积,进一步促进病变的发展和进展。

相似文献

1
Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls.纤溶酶原激活物抑制剂-1在人肝脏以及健康或动脉粥样硬化血管壁中的表达。
Thromb Haemost. 1994 Jul;72(1):44-53.
2
Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells.动脉粥样硬化斑块中的巨噬细胞产生1型纤溶酶原激活物抑制剂,并刺激内皮细胞和平滑肌细胞产生该物质。
Am J Pathol. 1993 Sep;143(3):875-85.
3
Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo.
J Mol Cell Cardiol. 1998 Aug;30(8):1535-43. doi: 10.1006/jmcc.1998.0719.
4
Low-density lipoproteins induce the polar secretion of PAI-1 by endothelial cells in culture.
Am J Hematol. 2003 May;73(1):66-8. doi: 10.1002/ajh.10314.
5
In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element.
Thromb Haemost. 2000 Oct;84(4):706-11.
6
C-type natriuretic peptide (CNP) suppresses plasminogen activator inhibitor-1 (PAI-1) in vivo.C型利钠肽(CNP)在体内可抑制纤溶酶原激活物抑制剂-1(PAI-1)。
Cardiovasc Res. 2005 Jun 1;66(3):574-82. doi: 10.1016/j.cardiores.2005.01.024. Epub 2005 Feb 25.
7
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.1型和3型纤溶酶原激活物抑制剂、尿激酶型纤溶酶原激活物蛋白及mRNA在乳腺癌中的表达
Thromb Res. 2007;120(5):753-62. doi: 10.1016/j.thromres.2006.12.016. Epub 2007 Jan 29.
8
Plasminogen activator inhibitor-1 is an immediate early response gene in regenerating rat liver.纤溶酶原激活物抑制剂-1是再生大鼠肝脏中的一个即时早期反应基因。
Cancer Res. 1994 Mar 1;54(5):1337-43.
9
Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients.动脉粥样硬化与慢性血液透析患者的纤溶酶原激活物抑制剂-1相关。
Nephrology (Carlton). 2008 Oct;13(7):579-86. doi: 10.1111/j.1440-1797.2008.00987.x.
10
[Expression and plasma activity of plasminogen activator inhibitor-1 infibrotic liver tissues].[纤化肝组织中纤溶酶原激活物抑制剂-1的表达及血浆活性]
Zhonghua Gan Zang Bing Za Zhi. 2000 Aug;8(4):209-11.

引用本文的文献

1
Why Are Internal Mammary (Thoracic) Arteries Less Prone to Developing Atherosclerosis Compared to Coronary Arteries? Do Gut Microbiota Play a Role? A Narrative Review.与冠状动脉相比,为什么胸廓内动脉更不易发生动脉粥样硬化?肠道微生物群起作用吗?一项叙述性综述
Int J Mol Sci. 2025 Sep 17;26(18):9052. doi: 10.3390/ijms26189052.
2
SERPINE1 mRNA Binding Protein 1 Is Associated with Ischemic Stroke Risk: A Comprehensive Molecular-Genetic and Bioinformatics Analysis of SNPs.丝氨酸蛋白酶抑制剂 E1 mRNA 结合蛋白 1 与缺血性脑卒中风险相关:SNP 的综合分子遗传与生物信息学分析。
Int J Mol Sci. 2023 May 13;24(10):8716. doi: 10.3390/ijms24108716.
3
Lipopolysaccharide acting via toll-like receptor 4 transactivates the TGF-β receptor in vascular smooth muscle cells.
脂多糖通过 Toll 样受体 4 转激活血管平滑肌细胞中的 TGF-β 受体。
Cell Mol Life Sci. 2022 Feb 5;79(2):121. doi: 10.1007/s00018-022-04159-8.
4
A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?纤溶酶原激活物抑制剂-1 的综述及其(病理)生理学作用:靶向还是不靶向?
Int J Mol Sci. 2021 Mar 8;22(5):2721. doi: 10.3390/ijms22052721.
5
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
6
Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.纤溶酶原激活物抑制剂-1的化学拮抗剂:作用机制及在血管疾病中的治疗潜力
J Mol Genet Med. 2014 Oct;8(3). doi: 10.4172/1747-0862.1000125.
7
A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage.一种小分子PAI-1功能抑制剂通过促进PAI-1裂解来减轻内膜增生和血管平滑肌细胞存活。
Cell Signal. 2015 May;27(5):923-33. doi: 10.1016/j.cellsig.2015.01.009. Epub 2015 Jan 22.
8
Small Molecule PAI-1 Functional Inhibitor Attenuates Vascular Smooth Muscle Cell Migration and Survival: Implications for the Therapy of Vascular Disease.小分子纤溶酶原激活物抑制剂-1功能抑制剂可减弱血管平滑肌细胞迁移和存活:对血管疾病治疗的意义。
New Horiz Transl Med. 2014 Sep 1;2(1):16-19. doi: 10.1016/j.nhtm.2014.08.003.
9
Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.纤溶酶原激活物抑制剂-1 表达改变对心血管疾病的影响。
Curr Drug Targets. 2011 Nov;12(12):1782-9. doi: 10.2174/138945011797635803.
10
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.纤溶酶原激活物抑制剂-1(PAI-1):连接纤维蛋白溶解和与年龄相关的亚临床及临床状况的关键因素。
Cardiovasc Ther. 2010 Oct;28(5):e72-91. doi: 10.1111/j.1755-5922.2010.00171.x. Epub 2010 Jul 7.